Enacts the medical psilocybin act

• Democratic14

◆ The sponsor's argument

Why Julia Salazar says this is needed

New York State is facing an ongoing mental health crisis marked by rising rates of major depressive disorder, post-traumatic stress disor- der (PTSD), end-of-life psychological distress, and chronic neurological conditions such as cluster headaches. For many New Yorkers suffering from these serious conditions, currently available treatments are insuf- ficient, ineffective, or accompanied by significant side effects. Treatment-resistant depression affects hundreds of thousands of individ- uals nationwide and is associated with increased hospitalization, disa- bility, suicide risk, and substantial economic costs. Veterans, first responders, terminally ill patients, and those suffering from debilitat- ing neurological disorders often exhaust conventional treatment options without meaningful relief. Emerging scientific evidence demonstrates that psilocybin-assisted therapy offers a promising, evidence-based intervention capable of producing rapid, durable, and clinically signif- icant symptom improvement in patients who have failed to respond to existing therapies. * Clinical trials conducted at leading institutions, including Johns Hopkins University, New York University, and Yale, have demonstrated substantial reductions in depressive symptoms, anxiety associated with terminal illness, and trauma-related psychological distress when psilocybin is administered in a controlled therapeutic setting with professional supervision. Additionally, preliminary research and patient-reported outcomes suggest psilocybin may provide significant relief for cluster headaches, one of the most painful neuro- logical disorders known to medicine. ** New York has long been at the forefront of progressive public health policy and is uniquely equipped, through its world-class academic medical centers and regulatory agencies, to implement a medically super- vised psilocybin program with rigorous safeguards, practitioner training requirements, patient screening protocols, and longitudinal research oversight. Such a program would not only provide new hope for patients suffering from severe and refractory illness, but would also generate critical clinical data to further refine best practices and guide future federal policy development. The legislature has both a moral and public health obligation to ensure that patients confronting profound psychological suffering are not denied access to promising therapies solely because existing law has failed to keep pace with modern medical science. Authorizing the medical use of psilocybin would offer compassionate relief to New Yorkers facing major depressive disorder, PTSD, terminal illness, and cluster head- aches, while preserving the highest standards of patient safety, profes- sional accountability, and scientific integrity. This legislation represents a prudent, research-driven response to some of the most difficult treatment challenges in modern medicine.

This is the sponsor's own case for the bill, quoted from their memorandum. It is not Agora's description of what the bill does.